At a Glance
- Companies: Merck & Co. (MSD outside US); Revolution Medicines, Inc. (Nasdaq: RVMD)
- Location: Kenilworth, New Jersey (Merck); Redwood City, California (Revolution)
- Deal value: Up to $28–32bn, per reports
- Focus area: Revolution’s RAS(ON) inhibitors, including daraxonrasib for KRAS‑mutant cancers
- Next steps: Finalise terms; potential competing bids could drive valuation higher
What happened?
Merck & Co. is reportedly in advanced talks to acquire cancer biotech Revolution Medicines in a deal valued at $28–32 billion, according to the Financial Times, marking one of the largest biotech M&A transactions since Pfizer’s $43 billion Seagen buyout. The discussions follow an earlier Wall Street Journal report of AbbVie interest, which AbbVie denied, leaving Merck as the frontrunner amid a competitive auction.
Why does it matter?
Merck faces a looming patent cliff for Keytruda (pembrolizumab), its $25 billion+ PD‑1 blockbuster, with exclusivity eroding post‑2028, necessitating pipeline replenishment in oncology. Revolution’s RAS(ON) inhibitors—targeting the active GTP‑bound state of mutant RAS proteins driving 30% of cancers (e.g. pancreatic, NSCLC, colorectal)—offer precision oncology assets with multi‑KRAS selectivity and phase 3 data expected in 2026.
Who’s behind it?
Revolution Medicines specialises in RAS inhibitors, with lead daraxonrasib (RMC‑6236) showing 35% ORR in pretreated pancreatic cancer and advancing in NSCLC/PDAC; other assets include elironrasib and zoldonrasib. Merck has ramped up oncology M&A, including $11.5 billion Acceleron (Winrevair) and $9.2 billion Cidara, to diversify beyond Keytruda.
How was it achieved?
Talks centre on an all‑cash or mixed deal valuing Revolution at a premium to its ~$20.8 billion market cap, with Revolution’s projected $10 billion+ risk‑adjusted peak sales by 2035 justifying the price despite no approved products. Multiple suitors could escalate bidding, but no final agreement exists, with closure potentially weeks away.
What’s next?
If consummated, the acquisition would integrate Revolution’s RAS pipeline into Merck’s oncology engine, accelerating phase 3 readouts and FDA filings by 2027–2028. Competing bids from other pharmas could push valuation over $32 billion, reshaping oncology M&A momentum into JPM 2026.
What are people saying?
FT sources noted Merck’s pursuit but emphasised no final deal, with other pharmas circling. Mizuho analysts project Revolution’s portfolio at $10bn+ sales by 2035, validating the premium. BioXconomy called it a “huge” post‑Keytruda move for Merck.